Asia-Pacific Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Industry Trends and Forecast to 2030.
Asia-Pacific Antiviral Drugs Market Analysis and Insights
The increasing awareness about viral infections Asia-Pacific has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of drug development techniques also contributes to the rising demand for antiviral drugs.
The Asia-Pacific antiviral drugs market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in the field of drug development is further boosting the market growth. However, difficulties such as the lack of standardized protocols and the lack of skilled professionals might hamper the growth of the Asia-Pacific antiviral drugs market in the forecast period.
Increasing healthcare expenditure on advancement and drug development is expected to give opportunities to the market. However, the increasing use of alternative treatments may challenge market growth. Data Bridge Market Research analyzes that the Asia-Pacific antiviral drugs market is expected to reach a value of USD 15,118.64 million by 2030, with a CAGR of 6.7% during the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, and Hetero. among others
|
Asia-Pacific Antiviral Drugs Market Definition
Antiviral drugs are medications used to treat viral infections by inhibiting the replication of viruses within host cells. These drugs target specific viruses or types of viruses and work by either preventing the virus from entering the host cell or by blocking key enzymes or proteins required for viral replication. Unlike antibiotics, which are used to treat bacterial infections, antiviral drugs are generally less effective, as viruses have a much simpler structure and rely on host cells to replicate. However, they can still be useful in treating some viral infections, such as influenza, herpes, and HIV.
Asia-Pacific Antiviral Drugs Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising prevalence of viral infections
Viral infections have steadily increased around the world during the past few decades. A virus that enters the body, exploits its cells for replication and spreads causes a viral infection. Viral infections can result in various symptoms, from minor to major, and in some instances, even life-threatening ones. Globalization is one of the main causes of the increase in viral infections. People travel and communicate with each other across boundaries, making the world more connected than ever. Viral transmission from one area to another has accelerated due to this enhanced connectedness.
Thus, the rising prevalence of viral infections is a complex issue with many contributing factors. Globalization, population density, climate change, and antibiotic resistance all influence the spread of viruses. Hence, it is expected to drive market growth.
- Advancements in new antiviral drug development
Antiviral treatments are prescribed to patients with viral infections. The creation of novel antiviral medications has made tremendous strides throughout time. These developments have lowered the disease burden, improved the treatment of viral infections, and saved lives. There is much development in the field of new antiviral drugs.
Thus, advancements in new antiviral drug development have improved the treatment of viral infections, reduced the disease burden, and are expected to drive market growth.
Restraint
- High cost of antiviral drugs
The high cost of antiviral drugs can have significant implications for patients and healthcare systems. Patients who cannot afford these medications may go without treatment or rely on inferior treatments, leading to worse health outcomes. In addition, the high cost of antiviral drugs can strain healthcare budgets, particularly in countries with limited resources.
Thus, the high cost of antiviral drugs is expected to restrain the Asia-Pacific antiviral drugs market.
Opportunity
-
Rising novel drug delivery systems
Research on antiviral medications has emphasized creating novel drug delivery mechanisms. Over conventional drug administration techniques, novel delivery systems have several benefits, such as improved bioavailability, tailored drug delivery, and fewer adverse effects.
Thus, developing novel drug delivery systems is an important area of research in antiviral drugs. Nanoparticle drug delivery systems, hydrogels, dendrimers, microneedles, and cell-penetrating peptides are some promising drug delivery systems that have been investigated for antiviral drugs. These delivery systems offer several advantages over traditional drug delivery methods and have the potential to improve the efficacy and safety of antiviral drugs and are expected to create an opportunity in the market's growth.
Challenge
- Patent expiration of antiviral drugs
The process of patent expiration results in the original developer or patent holder losing their exclusive right to produce and market a specific medicine. The patent expiration of antiviral medications may significantly impact the pharmaceutical business since it may invite competition from producers of generic medications.
Antiviral medications' patents expire at the end of the time in which their creator has the sole right to manufacture and market the medication. Following the expiration of a drug's patent, other producers can create and market generic versions. This may result in greater competition and lower consumer prices. HIV, hepatitis B and C, herpes, influenza, and other viral illnesses are all treated with antiviral medications. Antiviral medications' patents expire at different times depending on the drug and the nation. Drug patents are typically granted for 20 years from the date of filing. Other producers are free to create and market generic versions of medicine once its patent has expired. Because the producer does not have to spend as much on marketing, research and development, and clinical studies, generic medications are often more affordable than name-brand medications.
Thus, patent expiration of antiviral drugs can have significant implications for the availability, affordability, and accessibility of these important medications and is expected to act as a challenge to market growth.
Recent Developments
- In January 2023, Merck, known as MSD, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago Biosciences, Inc. (Nasdaq: IMGO), at a purchase price of USD 36.00 per share in cash, without interest and subject to deduction for any required tax withholding. The acquisition will help in the growth of the revenue.
- In April 2021, Zydus Pharmaceuticals, Inc. announced that it had received restricted emergency use approval from the Drug Controller General of India (DCGI) to use the antiviral drug Virafin for the treatment of moderate COVID-19 infections. This will help the company to increase its Asia-Pacific presence and reputation in other regions of the globe.
Asia-Pacific Antiviral Drugs Market Scope
The Asia-Pacific antiviral drugs market is segmented into six notable segments based on indication, patient type, products, drug type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Indication
- Influenza
- Human Immunodeficiency Virus (HIV)
- Hepatitis C Virus
- Herpes Simplex Virus
- Human Cytomegalovirus (HCMV)
- Varicella-Zoster Virus (VZV)
- Hepatitis B Virus
- Respiratory Syncytial Virus
- Coronavirus Infection
- Others
On the basis of indication, the Asia-Pacific antiviral drugs market is segmented into influenza, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus, herpes simplex virus, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), hepatitis B virus (HBV), coronavirus infection, and others.
Patient Type
- Child
- Adult
- Geriatric
On the basis of patient type, the Asia-Pacific antiviral drugs market is segmented into child, adult, and geriatric.
PRODUCTS
- Oral
- Topical
- Parenteral
On the basis of products, the Asia-Pacific antiviral drugs market is segmented into oral, topical, and parenteral.
Drug Type
- Generic
- Branded
On the basis of drug type, the Asia-Pacific antiviral drugs market is segmented into generic and branded.
End User
- Hospital
- Clinics
- Home Healthcare
- Speciality Centers
- Ambulatory Centers
- Others
On the basis of end user, the Asia-Pacific antiviral drugs market is segmented into hospitals, clinics, home healthcare, specialty centers, ambulatory centers, and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the Asia-Pacific antiviral drugs market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Asia-Pacific Antiviral Drugs Market Regional Analysis/Insights
The Asia-Pacific antiviral drugs market is categorized into six notable segments based on indication, patient type, products, drug type, end user, and distribution channel.
The countries covered in this market report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific.
In 2023, Japan dominates the Asia-Pacific region due to the strong presence of key players and due to the increasing demand from emerging markets and expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Antiviral Drugs Market Share Analysis
Asia-Pacific antiviral drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific antiviral drugs market.
Some of the major players operating in the Asia-Pacific antiviral drugs market are Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc, and Hetero. among others.
SKU-